In this episode of the Psychedelic Spotlight podcast, we speak with Dr. Ingmar Gorman who is the Co-Founder and Lead Trainer at Fluence, and a Principal Investigator for the Multidisciplinary Association for Psychedelic Studies ("MAPS").
Similar Posts
Dr. Matthew Johnson: Psychedelics, Consciousness, DMT Experiences & The CIA
In this much anticipated Psychedelic Spotlight podcast, we get to…
MindMed 2021 Year-End Conference Call and Earnings: Big Updates for MNMD Stock
MindMed 2021 Year-End Conference Call and Earnings: Big Updates for MNMD Stock
Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psychedelic-news/industry/
All Psychedelic Stock investors should take the time to listen to the conference calls of the companies they are investing in. That is doubly important for year-end calls, as often information is divulged on the direction of the company. If you are invested in MNMD or MMED stock, you need to listen to this call.
Follow us on Twitter:
The Psychedelic Investor: @psycInvestor
James: @Psy_Invest
Maria: @psy_holy
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
Meet Kevin O’Leary, Rober Barrow, Daniel Carcillo and other psychedelic leaders @ the Benzinga Psychedelics Capital Conference.on April 19 @ Fontainebleau Hotel, Miami!
https://www.eventbrite.com/e/benzinga-psychedelics-capital-conference-spring-2022-tickets-238697028237?discount=PSYCHSPOTLIGHT15&fbclid=IwAR3tJFhoVfVWZvAyQuWSLEo3kJSmaq8VGnQQPz04NMhG3g7rHtSmRSAUq64
COUPON CODE: PSYCHSPOTLIGHT15
Interested in going to Malta for Plant Medicine Week April 5th-8th? Get discounted tickets here: https://tickets.plantmedicineweek.com/attendance/event/index/41436/EN?promocodes=PSYC
In this MindMed 2021 conference and earnings call, we gained important insights into the company’s many projects. These include: Project Lucy, which attempts to treat Anxiety using LSD; Project Angie, attempting to treat pain with LSD; Project Layla, attempting to treat addiction with 18-MC, and much more.
The company gives some updates on the science of psychedelics, as well as their hiring strategy and financial updates. MindMed is a company working on treating mental health conditions with psychedelics. They are a leading player in the shroom boom, and they aim to commercialize psychedelics as medicines.
Some of the questions MindMed is trying to answer are:
Can Psychedelics treat Mental Health conditions?
Can Psychedelics treat depression?
Can Psychedelics treat anxiety?
Can Psychedelics treat ADHD?
Can Psychedelics help with Autism?
Can Psychedelics help treat pain?
#MindMed #MNMD #MindMedStocks
Numinus & Cybin Forge MASSIVE DEALS ( NUMI / CYBN )
BIG news for Cybin Inc. (CYBN: NEO) (CLXPF: OTC) and Numinus Wellness (NUMI: NEO)
(LKYSF: OTC).
First and foremost, Numinus announced that the company acquired NCT, a Toronto-based, fully operational neurology center with 13 doctors, 8 allied health staff, nurse practitioners, and physician assistants. NCT and Numinus plan to establish the first center for excellence in psychedelic neurology.
Speaking of centers of excellence, Cybin entered into an agreement with a company called Greenbrook TMS to establish mental health centers of excellence in order to facilitate R & D of psychedelic compound-based therapeutics for patients suffering from depression.
Why is this big news? Watch till the end to find out!
In other news, we are glad to announce that The Psychedelic Investor has entered into a collaboration with Psychedelic Spotlight, one of the biggest news sources for psychedelic-related news.
Twice a month, I will be discussing some of the major industry news among other psychedelic industry experts in Psychedelic Spotlight’s segment titled: “Spotlight Roundup”.
Check out my first appearance on their podcast by clicking the link below!
https://www.youtube.com/watch?v=UKGFXnsOlr8
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Timestamps
0:00 -Intro
2:40 – Numinus Acquisition of Neurology Center of Toronto
9:55 -Cybin Enters Agreement with Greenbrook
Links:
NUMINUS WELLNESS TO ACQUIRE NEUROLOGY CENTRE OF TORONTO, PLANS TO CREATE CENTRE FOR PSYCHEDELIC NEUROLOGY:
https://thepsychedelicinvestor.com/2021/07/06/numinus-wellness-to-acquire-neurology-centre-of-toronto-plans-to-create-centre-for-psychedelic-neurology/
CYBIN (NEO: CYBN, OTC: CLXPF) ENTERS INTO COLLABORATION AGREEMENT WITH GREENBROOK TMS TO ESTABLISH MENTAL HEALTH CENTERS OF EXCELLENCE:
https://thepsychedelicinvestor.com/2021/07/08/cybin-enters-into-collaboration-agreement-with-greenbrook-tms-to-establish-mental-health-centers-of-excellence/
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#Numinus #Cybin #NUMIStock
MindMed Insiders DUMP Shares…AGAIN. Should we be Worried?
Here are my thoughts on MindMed’s CEO Jr Rahn and Board member Bruce Linton’s recent shares sell-off.
Resources:
How much JR sold from MMED/ MNMD:
https://thedeepdive.ca/mind-medicine-sees-ceo-sell-24-7-million-in-company-stock/
Stated reason for the sale:
https://twitter.com/PsilocybinAlpha/status/1397951345240461313/photo/1
How much MindMed stock JR Sold in the past:
https://seekingalpha.com/article/4411079-mind-medicine-great-potential-questionable-business-model
Insider selling SEC rules:
Sec rule regulation:
https://www.investopedia.com/terms/r/rule-10b5-1.asp
Canada and the SEC:
https://sec.report/CIK/0000230098
MindMed’s compensation packages as published on April 27, 2021
https://www.sedar.com/GetFile.do?lang=EN&docClass=10&issuerNo=00030583&issuerType=03&projectNo=03209908&docId=4942116
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
bruce linton image: https://www.rollingstone.com/culture/culture-news/bruce-linton-canopy-growth-ceo-fired-marijuana-855361/
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedNews #MindMedstock
Introducing the BENZINGA Psychedelic Capital Event | A Psychedelic Investor’s Dream
Buy your tickets to the Benzinga Psychedelics Capital Conference on…
Meet MindMed’s Interim CEO: Robert Barrow | My First Impressions & Comments
MindMed’s Interim CEO, Robert Barrow, has not made as many public appearances as opposed to MMED’s previous CEO, Jr Rahn.
As many of you know, almost two months ago, then MindMed’s CEO, JR Rahn, announced that he was stepping down, and he would be replaced immediately by Robert Barrow, then Chief Development Officer.
Since then, we have not had a lot of news from the company, and though we have heard from Barrow on previous Conference Calls, us the retail investors, have not had a chance to meet the man (at least digitally) as CEO yet.
That changed on August 3rd, when MNMD held a “fireside chat” over Zoom with Barrow, where we got to know him a little better, and he provided us with some new information.
In this video, we will play the most important clips and offer some commentary where necessary.
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MindMedStock #MNMD